Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.84 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | MITF | O75030 | 1/20 | 0.77 |
| ▸ | ALPL | P05186 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | ALPI | P09923 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALPG | P10696 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.75 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.75 |
| ▸ | XDH | P47989 | 1/20 | 0.75 |
| ▸ | RXRA | P19793 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.68 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425241 | 1.00 | PTPN1 (0.84) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| Glabrol SCHEMBL15602627 | 0.92 | PTPN1 (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| Glabrol SCHEMBL745275 | 0.92 | PTPN1 (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| Isobavachin SCHEMBL27013463 | 0.86 | SLC22A12 (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| Isobavachin SCHEMBL1170628 | 0.86 | SLC22A12 (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| Isobavachin SCHEMBL31620056 | 0.86 | SLC22A12 (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| SCHEMBL27013484 | 0.85 | PTPN1 (0.80) | PTPN1CYP1A1CYP1B1CYP19A1PLA2G1B | |
| SCHEMBL27811787 | 0.84 | RXRA (1.00) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| SCHEMBL29527169 | 0.83 | CYP3A4 (0.68) | PTPN1CYP1A1CYP1B1KDM4EMEN1 | |
| SCHEMBL1170822 | 0.81 | PTPN1 (0.77) | PTPN1CYP1A1CYP1B1CYP19A1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | BASF CORPORATION (US) | 2022-02-01 | — | — | US | claimed |
| EP-2858641-B1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORP (US) | 2017-09-06 | — | — | EP | claimed |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2015-05-21 | — | — | US | claimed |
| EP-2858641-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF Corporation (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013184884-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORPORATION (US) | 2013-12-12 | — | — | WO | claimed |
| US-20080305188-A9 | Composition and method for supporting cancer treatments | CHANG HSUN-LANG | 2008-12-11 | — | — | US | claimed |
| CN-101119711-A | Methods of use of herbal compositions | MEDIGREEN BIOTECHNOLOGY CORP (CN) | 2008-02-06 | — | — | CN | claimed |
| US-20070166404-A1 | Composition and method for supporting cancer treatments | MEDIGREEN BIOTECHNOLOGY CORP. (TW) | 2007-07-19 | — | — | US | claimed |
| EP-1784168-A1 | METHOD OF USE HERBAL COMPOSITIONS | Medigreen Biotechnology Corp. (TW) | 2007-05-16 | — | — | EP | claimed |
| WO-2006014788-A1 | METHODS OF USE OF HERBAL COMPOSITIONS | MEDIGREEN BIOTECHNOLOGY CORP. (TW) | 2006-02-09 | — | — | WO | claimed |
| EP-1620115-A1 | COMPOSITION AND METHOD FOR SUPPORTING CANCER TREATMENTS | Medigreen Biotechnology Corporation (TW) | 2006-02-01 | — | — | EP | claimed |
| US-20050025823-A1 | Methods of use of herbal compositions | MEDIGREEN BIOTECHNOLOGY CORP. (TW) | 2005-02-03 | — | — | US | claimed |
| WO-2004087186-A1 | COMPOSITION AND METHOD FOR SUPPORTING CANCER TREATMENTS | MEDIGREEN BIOTECHNOLOGY CORPORATION (TW) | 2004-10-14 | — | — | WO | claimed |
| US-20260027120-A1 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL IND INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021098-A1 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL IND INC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-119700748-A | Application of subprostrate sophora extract as inducer for inhibiting autophagy of thyroid undifferentiated carcinoma cells | 浙江工业大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-1370271-A2 | A PROCESS FOR THE MANUFACTURE OF A HERBAL COMPOSITION COMPRISING A MATRINE | Global Cancer Strategies Ltd. (CA) | 2003-12-17 | — | — | EP | disclosed |
| CN-1449812-A | Chinese herbal compound for treating extensive cancers | LI JIANYONG (CN) | 2003-10-22 | — | — | CN | disclosed |
| US-20030099725-A1 | Herbal compositions useful as chemopreventive and therapeutic agents and methods of manufacturing same | GLOBAL CANCER STRATEGIES LTD. | 2003-05-29 | — | — | US | disclosed |
| WO-2002067955-A2 | A PROCESS FOR THE MANUFACTURE OF A HERBAL COMPOSITION COMPRISING A MATRINE | GLOBAL CANCER STRATEGIES LTD. (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | ALG1, ALG8, CUTA | PTPN1 4794/4885CYP1A1 2372/4885CYP1B1 604/4885 |
| US-20260021098-A1 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | JAK2, JAK1, JAK3 | PTPN1 185/4885CYP1A1 53/4885CYP1B1 21/4885 |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | ALG1, ALG8, CUTA | PTPN1 4794/4885CYP1A1 2372/4885CYP1B1 604/4885 |
| US-20260027120-A1 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | JAK1, JAK2, JAK3 | PTPN1 161/4885CYP1A1 33/4885CYP1B1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.